# PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

> **NCT02216331** · PHASE1 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 32 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** TMC207
- **DRUG:** rifapentine
- **DRUG:** rifampicin

## Key facts

- **NCT ID:** NCT02216331
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216331, "PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02216331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*